These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23524591)

  • 1. Efficacy of an adapted granzyme B-based anti-CD30 cytolytic fusion protein against PI-9-positive classical Hodgkin lymphoma cells in a murine model.
    Schiffer S; Hansen HP; Hehmann-Titt G; Huhn M; Fischer R; Barth S; Thepen T
    Blood Cancer J; 2013 Mar; 3(3):e106. PubMed ID: 23524591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The intracellular granzyme B inhibitor, proteinase inhibitor 9, is up-regulated during accessory cell maturation and effector cell degranulation, and its overexpression enhances CTL potency.
    Hirst CE; Buzza MS; Bird CH; Warren HS; Cameron PU; Zhang M; Ashton-Rickardt PG; Bird PI
    J Immunol; 2003 Jan; 170(2):805-15. PubMed ID: 12517944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a human immuno-oncology therapeutic agent targeting HER2: targeted delivery of granzyme B.
    Cheung LH; Zhao Y; Alvarez-Cienfuegos A; Mohamedali KA; Cao YJ; Hittelman WN; Rosenblum MG
    J Exp Clin Cancer Res; 2019 Jul; 38(1):332. PubMed ID: 31362764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel fully-human cytolytic fusion protein based on granzyme B shows in vitro cytotoxicity and ex vivo binding to solid tumors overexpressing the epidermal growth factor receptor.
    Niesen J; Hehmann-Titt G; Woitok M; Fendel R; Barth S; Fischer R; Stein C
    Cancer Lett; 2016 May; 374(2):229-40. PubMed ID: 26912070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic efficacy and safety of a human fusion construct targeting the TWEAK receptor Fn14 and containing a modified granzyme B.
    Alvarez de Cienfuegos A; Cheung LH; Mohamedali KA; Whitsett TG; Winkles JA; Hittelman WN; Rosenblum MG
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32958685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of the nuclear localizing cytolytic granule serine protease granzyme B with importin alpha or beta: modulation by the serpin inhibitor PI-9.
    Blink EJ; Jiansheng Z; Hu W; Calanni ST; Trapani JA; Bird PI; Jans DA
    J Cell Biochem; 2005 Jun; 95(3):598-610. PubMed ID: 15791691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel Granzyme B nanoparticle delivery system simulates immune cell functions for suppression of solid tumors.
    Qian X; Shi Z; Qi H; Zhao M; Huang K; Han D; Zhou J; Liu C; Liu Y; Lu Y; Yuan X; Zhao J; Kang C
    Theranostics; 2019; 9(25):7616-7627. PubMed ID: 31695790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Granzyme M as a novel effector molecule for human cytolytic fusion proteins: CD64-specific cytotoxicity of Gm-H22(scFv) against leukemic cells.
    Schiffer S; Letzian S; Jost E; Mladenov R; Hristodorov D; Huhn M; Fischer R; Barth S; Thepen T
    Cancer Lett; 2013 Dec; 341(2):178-85. PubMed ID: 23973499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system?
    Bladergroen BA; Meijer CJ; ten Berge RL; Hack CE; Muris JJ; Dukers DF; Chott A; Kazama Y; Oudejans JJ; van Berkum O; Kummer JA
    Blood; 2002 Jan; 99(1):232-7. PubMed ID: 11756176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction and characterization of novel, completely human serine protease therapeutics targeting Her2/neu.
    Cao Y; Mohamedali KA; Marks JW; Cheung LH; Hittelman WN; Rosenblum MG
    Mol Cancer Ther; 2013 Jun; 12(6):979-91. PubMed ID: 23493312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanistic studies of a novel human fusion toxin composed of vascular endothelial growth factor (VEGF)121 and the serine protease granzyme B: directed apoptotic events in vascular endothelial cells.
    Liu Y; Cheung LH; Thorpe P; Rosenblum MG
    Mol Cancer Ther; 2003 Oct; 2(10):949-59. PubMed ID: 14578460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted delivery of human pro-apoptotic enzymes to tumor cells: In vitro studies describing a novel class of recombinant highly cytotoxic agents.
    Liu Y; Cheung LH; Hittelman WN; Rosenblum MG
    Mol Cancer Ther; 2003 Dec; 2(12):1341-50. PubMed ID: 14707275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of an artificial human B cell line test system using Transpo-mAbTM technology to evaluate the therapeutic efficacy of novel antigen-specific fusion proteins.
    Klose D; Woitok M; Niesen J; Beerli RR; Grawunder U; Fischer R; Barth S; Fendel R; Nachreiner T
    PLoS One; 2017; 12(7):e0180305. PubMed ID: 28704435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human microtubule-associated protein tau mediates targeted killing of CD30(+) lymphoma cells in vitro and inhibits tumour growth in vivo.
    Hristodorov D; Nordlohne J; Mladenov R; Huhn M; Fischer R; Thepen T; Barth S
    Br J Haematol; 2014 Jan; 164(2):251-7. PubMed ID: 24164493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and characterization of a novel human Granzyme B inhibitor.
    Marcet-Palacios M; Ewen C; Pittman E; Duggan B; Carmine-Simmen K; Fahlman RP; Bleackley RC
    Protein Eng Des Sel; 2015 Jan; 28(1):9-17. PubMed ID: 25492933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased number of granzyme B+ activated CD8+ cytotoxic T lymphocytes in the inflammatory background of HIV-associated Hodgkin's lymphoma.
    Bosch Príncep R; Lejeune M; Salvadó Usach MT; Jaén Martínez J; Pons Ferré LE; Alvaro Naranjo T
    Ann Hematol; 2005 Oct; 84(10):661-6. PubMed ID: 15875183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD30-targeted oncolytic viruses as novel therapeutic approach against classical Hodgkin lymphoma.
    Hanauer JDS; Rengstl B; Kleinlützum D; Reul J; Pfeiffer A; Friedel T; Schneider IC; Newrzela S; Hansmann ML; Buchholz CJ; Muik A
    Oncotarget; 2018 Feb; 9(16):12971-12981. PubMed ID: 29560124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apoptotic death concurrent with CD3 stimulation in primary human CD8+ T lymphocytes: a role for endogenous granzyme B.
    Laforge M; Bidère N; Carmona S; Devocelle A; Charpentier B; Senik A
    J Immunol; 2006 Apr; 176(7):3966-77. PubMed ID: 16547231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surface charge-modification prevents sequestration and enhances tumor-cell specificity of a recombinant granzyme B-TGFα fusion protein.
    Jabulowsky RA; Oberoi P; Bähr-Mahmud H; Dälken B; Wels WS
    Bioconjug Chem; 2012 Aug; 23(8):1567-76. PubMed ID: 22759275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted ex vivo reduction of CD64-positive monocytes in chronic myelomonocytic leukemia and acute myelomonocytic leukemia using human granzyme B-based cytolytic fusion proteins.
    Schiffer S; Rosinke R; Jost E; Hehmann-Titt G; Huhn M; Melmer G; Barth S; Thepen T
    Int J Cancer; 2014 Sep; 135(6):1497-508. PubMed ID: 24523193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.